RA CAPITAL MANAGEMENT LLC 13D and 13G filings for Cytek Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:29 pm Sale | 2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 0 0.000% | -6,809,404 (Position Closed) | Filing |
| 2024-02-22 7:07 pm Unchanged | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 6,809,404 5.200% | 0 (Unchanged) | Filing |
| 2023-09-19 5:25 pm Sale | 2023-09-15 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 6,809,404 4.990% | -6,329,923 (-48.18%) | Filing |
| 2022-03-14 5:04 pm Purchase | 2022-03-10 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 13,139,327 9.800% | 2,057,164 (+18.56%) | Filing |
| 2022-02-28 5:29 pm Purchase | 2022-02-28 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 11,082,163 8.300% | 1,475,135 (+15.35%) | Filing |
| 2021-08-06 4:30 pm Purchase | 2021-07-27 | 13D | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT LLC | 9,607,028 7.200% | 9,607,028 (New Position) | Filing |